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a  b  s  t  r  a  c  t
Individuals  vary  in  their  initial  reactions  to  drugs  of  abuse  in  ways  that  may  contribute  to  the  likelihood  of
subsequent  drug  use.  In humans,  most  drugs  of  abuse  produce  positive  subjective  states  such as  euphoria
and  feelings  of well-being,  which  may  facilitate  repeated  use.  In nonhumans,  many  drugs  initially  increase
locomotor  activity  and  produce  discriminative  stimulus  effects,  both  of  which  have  been  considered  to  be
models  of human  stimulant  and  subjective  states.  Both  humans  and  nonhumans  vary  in their  sensitivity
to  early  acute  drug  effects  in ways  that  may  predict  future  use or  self-administration,  and  some  of  these
variations  appear  to be genetic  in  origin.  However,  it  is  not  known  exactly  how  the initial  responses  to
drugs  in  either  humans  or nonhumans  relate  to subsequent  use  or  abuse.  In humans,  positive  effects  of
drugs facilitate  continued  use of a  drug  while  negative  effects  discourage  use,  and  in  nonhumans,  greater
genetic  risk  for drug  intake  is  predicted  by reduced  sensitivity  to drug  aversive  effects;  but  whether  these
initial  responses  affect  escalation  of drug  use,  and  the  development  of dependence  is  currently  unknown.
Although  early  use  of  a drug  is a  necessary  step  in  the  progression  to  abuse  and  dependence,  other  vari-
ables  may  be  of  greater  importance  in the  transition  from  use  to abuse.  Alternatively,  the  same  variables
that  predict  initial  acute  drug  effects  and  early  use  may  significantly  contribute  to continued  use,  esca-
lation  and dependence.  Here  we review  the  existing  evidence  for  relations  between  initial  direct  drug
effects,  early  use,  and  continued  use.  Ultimately,  these  relations  can  only be  determined  from  systematic
longitudinal  studies  with  comprehensive  assessments  from  early  drug  responses  to  progression  of  prob-
lem drug  use.  In parallel,  additional  investigation  of  initial  responses  in  animal  models  as  predictors  of
drug use will  shed  light  on the  underlying  mechanisms.
© 2012  Elsevier  Ltd.  All  rights  reserved.
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1. Introduction
Most drugs of abuse produce subjective feelings of well-being
and euphoria in humans, which are thought to contribute to the
drug’s potential to be used or abused (de Wit  and Griffiths, 1991;
Fischman and Foltin, 1991). Indeed, drug-induced changes in mood
or subjective state have long been the primary indicator of abuse
potential used by the Food and Drug Administration (FDA) to assess
the likelihood of abuse for new medications (Jasinski, 1991; FDA
guidelines in Balster and Bigelow, 2003; Carter and Griffiths, 2009).
Drugs that produce euphoria are more likely to be abused than
drugs that fail to produce euphoria, and individuals who  report
experiencing more positive effects from a drug are more likely to
use the drug again. However, the extent to which either the qual-
ity or magnitude of responses to the first few exposures to a drug
are indicators of the individual’s likelihood of continued use, or
in the longer term to abuse or dependence, remains to be deter-
mined. The full clinical manifestation of drug dependence results
from dynamic changes that occur only after repeated administra-
tion of the drug, including alterations related to learning, tolerance,
cognitive function, stress, sensitization and complex neuroadapta-
tions underlying these phenomena (Everitt et al., 2008). Thus, the
relationship between early subjective responses and fully devel-
oped dependence is at best indirect (Wagner and Anthony, 2002).
Yet, there is evidence that an individual’s initial responses to drugs
may  constitute one factor contributing to the risk for future abuse
or dependence. This is of particular interest because of the possibil-
ity that genetic factors may  influence these initial responses, and
thus impart vulnerability to future use.
2. Individual differences in responses to drugs
Individuals may  differ in their responses to drugs on several
dimensions, any of which may  influence subsequent use. Indi-
viduals may  differ in how the drug makes them feel (i.e., the
subjective self-reported states in humans; discriminative stimulus
effects in animals), how it affects physiological processes (e.g., heart
rate; body temperature) or how it affects their behavior (e.g., risk-
taking behavior in humans; locomotor activation or depression in
rodents). Further, responses to drugs may  vary in magnitude (i.e.,
greater or lesser sensitivity), the quality of effects (e.g., stimulant-
like or sedative-like), the affective valence of the effects (e.g., liking,
disliking), and the time course (e.g., onset or duration). These vari-
ations in acute drug effects may  be genetic or nongenetic in origin.
Further, several of these dimensions have been implicated in the
etiology of drug abuse or dependence. For example, Conrod et al.
(2001) suggest that the amount of increase in heart rate after alco-
hol is a positive indicator of risk for abuse, and Schuckit (1987) and
others have suggested that low level of intoxication-like response
to alcohol is a risk factor for future alcohol dependence. Evidence
for the causal role of these potential predictors is difficult to obtain
in humans. In nonhumans, there is also a literature examining
the relation between initial responses to drugs and future drug
self-administration (see below). Advantages of the animal models
include the degree of control over the animals’ drug use history, and
the capacity to manipulate genetic variables. Although a compre-
hensive review of the nonhuman mammalian literature is beyond
the scope of the present analysis, we  note some interesting sim-
ilarities between humans and nonhumans. It is also important to
mention that a potential source of variability affecting both ini-
tial responses to drugs and progression to use is variation in the
pharmacokinetic properties of a drug. For example, there is genetic
variation in the rate at which certain drugs are metabolized, which
may  affect sensitivity to drug effects and either increase or decrease
their risk for using the drug (Edenberg, 2007; Ho and Tyndale,
2007). The most common example of this factor is in the flushing
response to alcohol, which decreases risk for developing alcoholism
(see below).
2.1. Methods for studying the role of initial responses in humans
Information about the relationship between sensitivity to ini-
tial drug effects and subsequent use in humans can be obtained
from several sources, including retrospective studies with estab-
lished drug users, longitudinal studies with early drug users, and
laboratory-based studies involving drug choice. In retrospective
studies, drug abusers are asked to recall their early drug use expe-
riences (e.g., Haertzen et al., 1983). For some drug classes, these
retrospective studies provide the only available source of informa-
tion (e.g., opiate drugs in opiate abusers). However, retrospective
studies are limited by their reliance on memory and highly selective
bias in respondents, who  are usually drug users with many years of
drug experience. In prospective studies, initial responses to drugs
are assessed in young early or non-users, and then their recreational
use is followed over months or years (e.g., studies of early cigarette
smokers (Chen et al., 2003; described below)). These studies are
especially valuable because they provide a measure of initial drug
response, not biased by memory. However, they are expensive and
time-consuming, and are not possible for certain drug classes (e.g.,
illicit opiates). A further limitation of both retrospective and lon-
gitudinal studies is that initial drug effects are experienced under
naturalistic conditions where expectancies, other concurrent drug
use, and context can influence the apparent drug effect. In contrast,
in human laboratory studies, participants receive controlled doses
of drugs and are then allowed to consume and regulate their intake
of the drug (Chutuape and de Wit, 1994; de Wit, 1998). These stud-
ies often document the participants’ first experience with the drug,
unconfounded by expectancies or contextual factors. Participants
who report experiencing positive subjective drug effects (e.g., lik-
ing or euphoria) typically choose to consume the drug when given
the opportunity. This concordance provides support for the idea
that greater positive acute effects predict repeated use of the drug
within the laboratory setting, and perhaps outside the laboratory
as well. The measures of subjective drug effects are sensitive and
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reliable. Yet, in the context of opiate drugs, McAuliffe (1975)
noted that subjective drug experiences are sometimes difficult to
define, and subjects’ ratings of positive effects such as ‘euphoria’,
‘intoxication’, ‘high’ and ‘liking’ of the drug, may  not be readily dis-
tinguishable from their ratings of apparently negative effects such
as ‘nausea’, ‘sick’, ‘heavy’. Further, especially in the context of ini-
tially unpleasant drugs, users may  ‘learn to get high’, and adapt
to unpleasant side effects of the drug with repeated use. Thus, ini-
tially unpleasant subjective responses to certain drugs may  become
positive after relatively few uses.
2.2. Methods for studying the role of initial responses in
nonhumans
Several experimental approaches have been taken to study the
relationship between initial drug effects and use in nonhumans.
Individual variation in sensitivity to initial drug effects (e.g., loco-
motor behavior, sedative effects) can be examined in relation to
likelihood of initiating drug intake or amount consumed (e.g.,
Piazza et al., 1989; Pierre and Vezina, 1997). These studies pro-
vide some evidence that initial drug responses predict future use.
However, many of the existing studies used genetically heteroge-
neous populations (parallel to unselected populations of humans),
making it difficult to discern the specific roles of genetic and non-
genetic factors in sensitivity. Moreover, these studies sometimes
entail some initial drug exposure to identify a predictor trait, and
this exposure itself could affect the subsequent intake measure. An
alternative approach to studying the relation between initial drug
responses and drug intake, which avoids this problem, is to utilize
genetically defined types of animals to examine genetic correla-
tions between acute drug responses and drug self-administration
(e.g., Kamens et al., 2005). For example, this approach can be taken
using panels of inbred mouse and rat strains, selectively bred lines
of rodents and animals in which single genes have been manip-
ulated. These studies may  reveal common genetic factors that
influence both initial sensitivity and drug intake.
3. Specific examples of acute responses predicting use or
abuse
The extent to which sensitivity to acute drug effects in humans
predicts the trajectory of drug use outside the laboratory remains
to be determined. Clearly, a multitude of other factors contribute
to the etiology of drug abuse and dependence, including non-drug-
related factors such as stress and impulsivity, and drug factors that
only come into play after repeated ingestion of the drug in a specific
context such as conditioning, tolerance and sensitization (Everitt
et al., 2008). Recognizing that the initial reaction to a drug is but one
of many factors that contribute to compulsive drug use, we evalu-
ate evidence in humans and nonhumans that the initial drug effects
contribute to subsequent regular use of alcohol, nicotine, cannabis,
cocaine, caffeine and opiates. These drugs are included because they
are among the most commonly used or abuse drugs for which per-
tinent data are available. Other drug classes, such as hallucinogens,
benzodiazepines, barbiturates, inhalants and dissociative anesthet-
ics will not be discussed because there is not enough information
available.
We  review evidence from both humans and nonhuman mod-
els. The concordance from human to nonhuman findings depends
on the sensitivity and validity of the nonhuman models used. As
noted in several recent reviews examining the consilience between
rodent models and human measures of sensitivity to alcohol or
nicotine (Crabbe et al., 2010; O’Dell and Khroyan, 2009; Stephens
et al., 2011), there is a need for more refined measures in animals to
match the measures used with humans. Nevertheless, we  review
the existing evidence from the nonhuman models to address the
specific question, i.e., do initial responses to drugs predict future
use? This information will provide a context for studying variabil-
ity in early drug responses, related to both genetic and non-genetic
factors, in relation to continued use (e.g., Haberstick et al., 2011;
Lott et al., 2005).
3.1. Alcohol
3.1.1. Evidence from humans
One well-documented source of variation in acute responses
to alcohol stems from metabolic differences related to enzymes
involved in the degradation of alcohol (Edenberg, 2007). Cer-
tain individuals, notably those of East Asian descent, experience
an aversive facial flushing response after consuming alcohol, a
response that can also include nausea, discomfort and tachycardia.
The response is due to accumulation of the metabolite acetalde-
hyde, which can occur either from more rapid oxidation of alcohol
by alcohol dehydrogenase (ADH) or from slower oxidation of
acetaldehyde by aldehyde dehydrogenase (ALDH). Several genetic
variants have been identified that affect both of these enzymes,
and individuals affected by the flushing response have a markedly
lower probability of developing alcoholism, presumably because
of the aversive effects they experience after consuming alcohol
(Edenberg, 2007; Whitfield, 2002).
There is also well-described individual variation in the phar-
macodynamic profile of alcohol. Most of the studies that have
examined acute responses to alcohol as predictors of future alco-
hol use focus on young adults with a family history of alcoholism,
but who have not yet themselves developed the disorder. Alcohol
abuse and dependence are highly heritable, such that children of
alcoholics are 4–5 times more likely to become alcoholic them-
selves (Schuckit, 1985a). The processes that mediate this risk are
not understood, but one approach has been to compare responses
to an acute dose of alcohol in individuals with or without a fam-
ily history of alcoholism, while they are young and presumably
at risk but not yet dependent. Schuckit and his colleagues have
conducted an elegant series of studies addressing this question,
demonstrating that sons of alcoholics exhibit a distinctive “low
level of response” to certain effects of alcohol (Schuckit, 1984a,b,
1994). They found that sons of alcoholic fathers report less subjec-
tive intoxication and body sway after a moderate dose of alcohol
than men  without alcoholic relatives. These at-risk individuals also
exhibit less alcohol-induced body sway (Schuckit, 1985b, 1988),
smaller alcohol-induced alterations in cortisol, prolactin, and ACTH
levels, less intense changes in the P300 component of the event-
related potential and differential EEG effects (Ehlers and Schuckit,
1990; Schuckit, 1988; Schuckit et al., 1987a,b; Schuckit and Gold,
1988). The reduced level of response also occurs in daughters whose
fathers have a history of alcohol dependence (Eng et al., 2005). From
these data, Schuckit and colleagues proposed a low-level response
theory. Individuals who are insensitive to these effects of alcohol are
postulated to be more susceptible to future alcohol use, and ulti-
mately abuse, because they are unable to gauge their own  level of
intoxication, and because they need greater amounts of alcohol to
achieve the desired effects. In support of this idea, Schuckit (1994)
conducted a 10-year follow-up study showing that a low response
to alcohol predicted a four-fold increase in likelihood of develop-
ing future Alcohol Dependence (APA, 1994). These studies indicate
that lesser responses to alcohol, including certain subjective and
physiological responses, represent a risk factor not only for alcohol
use, but also for future alcohol abuse or dependence. However, as
noted next, alternatives to this theory have also been proposed.
An alternative to Schuckit’s low-level response theory was pro-
posed by Newlin and Thomson (1990),  and recently re-examined
by Newlin and Renton (2010).  These authors cite 36 studies in
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which high-risk family history positive individuals demonstrated
higher levels of early alcohol response compared to low-risk groups,
on measures ranging from subjective reports of alcohol effects
(e.g., stimulation, intoxication), to physiological effects (e.g., heart
rate and cortisol) and behavioral measures (e.g., memory impair-
ment). The authors noted that the studies that reported greater
effects typically measured responses very soon after drug admin-
istration (sooner than most of the Schuckit studies), and thus
proposed a differentiator model,  that high-risk individuals have
greater stimulant-like effects from alcohol during the ascending
limb of the breath alcohol curve and less sedative-like effects dur-
ing the descending limb. Thus, the models are consistent, but the
differentiator model takes into account the biphasic nature of alco-
hol’s effects. Hendler et al. (2011) provide an in-depth review of
the variations in the stimulant and sedative effects of alcohol across
individuals, and how these may  be related to future alcohol con-
sumption. There is consensus that relative predictive value of these
proposals (low level response vs. differentiator model) will only be
resolved with further, in-depth longitudinal studies.
Taken together, these studies with alcohol provide some sup-
port for the idea that variation in initial responses to alcohol can
predict levels of future alcohol use. Yet, the findings are complex
and sometimes conflicting. Acute alcohol effects that are clearly
unpleasant (e.g., flushing) appear to discourage drinking. Either
greater stimulant effects or lesser sedative effects appear to predict
escalation of drinking. Notably, however, alcohol challenge stud-
ies in the United States typically include participants 21 years of
age and older, whose responses may  already be influenced by prior
experience. Assessing responses to alcohol at an earlier age would
provide more accurate measure of biological response and poten-
tial risk. Indeed, to the extent that early age of onset of drinking is a
predictor of future abuse (Grant, 1998; Moss et al., 2007), the first
experiences of greatest importance may  occur much earlier than 21
years of age. It is not even known whether acute response to alco-
hol is systematically related to age during the early, vulnerable ages.
Another limitation to the human alcohol challenge studies is that
most studies have tested healthy, young, usually Caucasian, volun-
teers without psychiatric or other substance disorders. Considering
the prevalence of psychiatric comorbidity between alcohol depen-
dence and other psychiatric conditions, it would be of particular
interest to examine early responses to alcohol among individuals
with psychiatric disorders or dysregulated HPA function. It is also
likely that there are multiple trajectories to alcohol dependence
such as the type 1 higher functioning, environmentally influenced
alcoholism, and the type 2 male-predominant familial, severe alco-
holism characterized by onset before age 25 (Cloninger et al., 1981).
A recent large-scale study suggested that there are as many as five
different subtypes, each with a distinctive etiology and trajectory
(Moss et al., 2007). Initial reactions to alcohol may  play a differ-
ent role in these subtypes (e.g., Gordh et al., 2011). Future research
on the relation between initial alcohol responses and alcohol use
disorders may  help to refine these subtypes and their biological
mechanisms.
3.1.2. Evidence from nonhumans
In nonhumans, metabolic factors have also been considered.
An Aldh type 2 knockout mouse that has high acetaldehyde levels
in blood, brain and liver after alcohol exposure (Isse et al., 2005),
exhibits a reduced preference for alcohol (Isse et al., 2002). Further,
alcohol has differential effects on Aldh type 2 gene expression in
different strains of mice, that correspond with their differences in
alcohol preference, indicating a genetic correlation between these
traits. A more modest correlation was found between Adh type
1 gene expression and alcohol preference in these mouse strains
(Tagliabracci and Singh, 1996). However, the role of these enzymes
in the brain appears to be more complicated, as there is also
evidence that these alcohol metabolizing enzymes in the brain may
play a positive role in the reinforcing effects of alcohol (Karahanian
et al., 2011). These authors suggest that alcohol serves as a
prodrug for acetaldehyde, and that acetaldehyde serves as the
active reinforcing drug. This builds on an older literature suggest-
ing that acetaldehyde plays a role in alcohol self-administration
(e.g., Amit et al., 1977). In addition, metabolites of alcohol, such as
acetate, may  be another source of variation in sensitivity to aversive
effects of alcohol that influences alcohol consumption (Maxwell
et al., 2010).
The animal alcohol literature provides mixed support for the
idea that alcohol sensitivity is associated with level of alcohol use.
As with the human findings just described, sensitivity in animals is
not a singular concept, and has been measured in many ways. For
example, one commonly used measure of alcohol sensitivity in ani-
mals is locomotor activity. Alcohol can either increase or decrease
locomotor activity, depending upon the dose of alcohol and the
time after alcohol administration at which behavior is measured.
Mice bred to have a greater locomotor stimulant response to alco-
hol early after administration (Crabbe et al., 1987; Phillips et al.,
2002) consume more alcohol (Risinger et al., 1994). To the extent
that locomotor activity represents stimulant-like positive effects,
this is consistent with the idea that greater sensitivity to positive
stimulant effects of alcohol predicts more alcohol use. Also, consis-
tent with both the differentiator and low level of response models,
the higher alcohol consuming line of mice are less sensitive to the
sedative-hypnotic and some ataxic effects of alcohol (Shen et al.,
1996; Phillips et al., 2002; but see Boehm et al., 2000). In addi-
tion, using data from several laboratories collected in a panel of
inbred rat strains, a correlational approach and subsequent factor
analysis offered some support for a relationship between higher
alcohol intake and lower initial sensitivity to sedative-intoxicating
effects of alcohol (Spuhler and Deitrich, 1984). These findings,
taken together with data from inbred mouse strains, examining
sensitivity-intake relationships (Ozburn et al., 2010; Crabbe et al.,
2010) provide inconclusive evidence for the relation between initial
stimulant effects and subsequent alcohol consumption.
Lines of mice and rats have also been bred for their large
differences in alcohol consumption, but the findings have been
mixed, with regard to their initial sensitivity to alcohol. The low
level of response relationship with high intake has received some,
but not perfect, support for some sedative and ataxic effects of
alcohol (Colombo et al., 2000; Crabbe et al., 2010; Files et al.,
1996; Kurtz et al., 1996; Lumeng et al., 1982; Phillips and Crabbe,
1991; Schechter, 1992). Also, a relationship of a greater stimu-
lant response with higher alcohol drinking has sometimes been
supported (Agabio et al., 2001; Krimmer, 1992; Krimmer and
Schechter, 1992; Quintanilla, 1999; Rodd et al., 2004; Waller et al.,
1986), but in other cases has not (Grahame et al., 2000; Paivarinta
and Korpi, 1993; Phillips et al., 2005, 1995). Some of the dispar-
ity is likely due to the genetic heterogeneity of alcohol drinking,
something that must be considered in outcomes from both humans
and nonhumans. For example, gene-specific research has identified
mechanisms that could underlie a relationship between alcohol
sensitivity and consumption (e.g., Hodge et al., 1999; Kim et al.,
2011; Naassila et al., 2002; Thiele et al., 2000). However, correspon-
dence of sensitivity with consumption, not surprisingly, has not
been found for all genetic manipulations that have been examined
(Crabbe et al., 2006).
In rodent studies, conditioned aversive effects of alcohol
assessed soon after administration are negatively correlated with
consumption. Lines of rats and mice that were bred for higher
levels of alcohol consumption also exhibit reduced sensitivity to
the conditioned aversive effects of alcohol (Chester et al., 2003;
Froehlich et al., 1988; Quintanilla et al., 2001), and conversely, ani-
mals bred for greater conditioned aversion consumed less alcohol
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(Phillips et al., 2005). Similar results have been found in pairs, pan-
els and crosses of inbred strains (Broadbent et al., 2002; Horowitz
and Whitney, 1975; Ozburn et al., 2010; Risinger and Cunningham,
1992; however, see Cailhol and Mormede, 2002; Risinger and
Cunningham, 1998). In general, although exceptions can be found
in the literature, the data suggest that there is a genetic relation-
ship between these traits, and that sensitivity to the aversive effects
of alcohol serves as a protective factor against excessive alcohol
intake. In humans, the initial aversive effect of alcohol has not been
systematically studied as a predictor of future use, except in the
context of the flushing response in Asians.
In nonhumans, information about the interoceptive effects of
alcohol, or how alcohol makes animals “feel”, is obtained using
drug discrimination methods. In these studies, the animal indi-
cates whether an ingested or injected solution “feels” (or tastes)
like alcohol or not, usually by pressing an alcohol-associated
or non-alcohol-associated lever. The findings from these studies
examining the quality and magnitude of interoceptive effects of
alcohol in relation to the propensity to self-administer alcohol have
been mixed (Gordon et al., 1993; Krimmer, 1992; Krimmer and
Schechter, 1992; McMillan and Li, 1999, 2001; McMillan et al.,
1999; York, 1981). However, it was recently shown that chronic
exposure to the stress hormone corticosterone blunted the ability
of rats to identify alcohol (Besheer et al., 2012). This is consistent
with the idea that chronic stress may  reduce the subjective effects
of alcohol in humans, leading an individual to consume more alco-
hol to achieve the desired effect.
3.2. Nicotine
3.2.1. Evidence from humans
Nicotine is a particularly interesting and paradoxical case for
examining the idea that initial, acute responses to drugs predict
progression to repeated use. Nicotine (or tobacco) is unique among
other drugs of abuse in that its initial subjective effects are typi-
cally not pleasant, and indeed often include unpleasant experiences
such as nausea and dizziness. As a result, it is often thought that
early use of tobacco is determined more by environmental influ-
ences (e.g., peer pressure) than by pleasant pharmacological effects.
Eissenberg and Balster (2000) reviewed the literature on early
responses to tobacco in relation to risk for regular smoking. Their
review included both retrospective studies assessing memories of
early responses among individuals who have tried smoking, as well
as longitudinal studies assessing early responses to smoking among
pre-adolescents and adolescents. There are several more recent
longitudinal studies, and there is also epidemiological evidence
relating cigarette smoking to variations in enzymes involved in the
metabolism of nicotine.
Several retrospective studies have examined participants’ recol-
lections of their initial responses to smoking, as possible predictors
of progression. Haertzen et al. (1983) conducted an early retro-
spective study with opiate abusers who were asked to recall their
early experiences with nicotine and other drugs. Whereas they
reported pleasurable initial responses to heroin and cocaine which,
they claimed, influenced subsequent use, they remembered expe-
riencing mainly unpleasant initial effects from tobacco, and that
these effects were unrelated to their subsequent smoking. In their
review of initial response as predictor of smoking, Eissenberg and
Balster (2000) found mixed results: in some studies, fewer dys-
phoric effects from initial cigarettes predicted smoking, whereas
in other studies more positive effects predicted future smoking.
More recently, DiFranza et al. (2004) interviewed 237 seventh
graders who had ever inhaled tobacco smoke, regarding their ini-
tial sensitivity to effects of nicotine. Relaxation was  the strongest
predictor of progression to subsequent smoking, but surprisingly
and counter-intuitively, nausea, or dizziness also independently
predicted progression. Similarly, Chen et al. (2003) surveyed 610
10th grade students who had ever tried smoking. After control-
ling for age and gender, pleasurable cigarette smell, pleasurable
buzz/rush, relaxation and dizziness predicted continued smoking.
The finding that pleasant cigarette smell was  a predictor is inter-
esting in light of preclinical evidence that nicotine may  enhance
the value of environmental stimuli that have some motivational
value because of their association with primary rewards (Caggiula
et al., 2009; Chaudhri et al., 2006). Alternatively, it is possible that
cigarette smell was  pleasant because of previous associations with
smoking (e.g., parents who smoked). Whether these remembered
initial responses to smoking were accurate, and whether they were
causally related to progression, cannot be determined from these
retrospective studies.
Several prospective studies have examined the relation between
initial sensations and later dependence. DiFranza et al. (2007) stud-
ied 217 sixth graders who  had ever inhaled tobacco smoke, and
followed them for 4 years. They found that feelings of relaxation
after initial smoking predicted nicotine dependence, or “loss of
autonomy over smoking” and dependence (WHO, 1992) 4 years
later. Other predictors were familiarity with popular cigarette
advertisements (e.g., Joe Camel), novelty seeking and depressed
mood. Kandel et al. (2007) conducted a 2-year longitudinal study
with 353 6th to 10th graders who  had tried a cigarette within the
year before the study or during the study. About 25% of the sample
developed Nicotine Dependence (APA, 1994) over a 2-year period,
and pleasant initial sensitivity to tobacco smoke was among the
best predictors of developing dependence. These authors took care
to obtain ratings of pleasantness and unpleasantness with regard to
sensations such as dizzy, rush, and buzz, and concluded that sensa-
tions that were regarded as pleasant were most predictive. Several
other studies have reported similar results (Audrain-McGovern
et al., 2007; Hu et al., 2006). More recently, Buchmann et al. (2011)
followed a cohort of German adolescents who had ever tried smok-
ing, from age 15 until 22, to identify determinants of progression.
They found that earlier age of smoking was associated with more
pleasurable sensations from the first cigarette and, although both
predicted progression to regular smoking, the age of smoking initi-
ation was  the more robust predictor of progression to dependence.
The question of whether the subjective or behavioral effects of
acute nicotine, or other drugs, vary with age, especially at younger
ages, is of critical importance and may  explain differences in vul-
nerability. Ethical concerns about administering drugs to children
and adolescents make it unlikely that these important studies will
be done. Taken together, however, the prospective studies that
have been conducted add to the evidence that initial responses
to nicotine contribute to the likelihood of escalation from use to
dependence.
Perkins and colleagues have studied subjective responses to
acute nicotine in relation to consumption in controlled studies
in healthy volunteers (Perkins et al., 2001, 2000, 2008). In one
study (Perkins et al., 2001), nonsmokers sampled a nicotine nasal
spray, and then had the opportunity to ingest it again. Subjects who
reported more positive effects from the spray were more likely to
take it again, whereas subjects who  experienced negative effects
were less likely to take it again. In another study (Perkins et al.,
2008), they examined subjects’ responses to intranasal nicotine
in relation to retrospective reports of early smoking experiences.
Adult nonsmokers who  had smoked only 1–10 times in their life-
time and remembered feeling dizzy and buzzed from their first
cigarette also reported these same effects after receiving nicotine
in a nasal spray. They described the effects as unpleasant, which
may have contributed to their non-continuation of smoking.
As is the case for alcohol, pharmacokinetic factors may  influence
rates of smoking, and perhaps early responses to smoking (Audrain-
McGovern et al., 2007; Ho and Tyndale, 2007). The metabolic
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inactivation of nicotine is controlled by genes such as CYP2A6 that
encodes a hepatic enzyme that affects most of the metabolism of
nicotine to cotinine (Benowitz and Jacob, 1994). Some studies have
reported that variations in this gene predict nicotine dependence:
slower metabolizers, who have genetic variants associated with
less than half of the activity of normal metabolizers, smoke fewer
cigarettes and are less likely to be current smokers (Malaiyandi
et al., 2006). However, this genetic relationship has not always
been found (Carter et al., 2004). Whether metabolic factors play
a role during early smoking experiences remains to be determined.
Audrain-McGovern et al. (2007) examined the role of pharmacoki-
netic variation in early onset of smoking, in adolescents from grades
9 to 12. Normal metabolizers progressed to nicotine dependence at
a faster rate than slow metabolizers, and these increases in nico-
tine dependence leveled off more slowly compared with slower
metabolizers. However, they found that initial subjective experi-
ences from smoking were not related to the genotypes, nor were
they predictive of nicotine dependence.
Thus, the studies with early responses to nicotine provide
mixed evidence for the relation between early acute response and
smoking progression. Some studies found that initial feelings of
relaxation or pleasurable buzz predicted progression, whereas oth-
ers found that dizziness and even nausea predicted future smoking.
Yet other studies found that early responses that were unpleas-
ant decreased the likelihood of progression. These highly variable
findings suggest that early positive subjective responses to nicotine
may  play a minor role in the development of smoking, and that per-
haps magnitude of any subjective response (positive or negative)
may  be predictive. Alternatively, other factors related to context,
learning and neurobiological adaptations may  be more important
for this drug.
3.2.2. Evidence from nonhumans
In animals, nicotine also has competing positive and aversive
effects. Nicotine self-administration in animals has typically been
studied using intravenous (IV) methods, and dose-response curves
for IV self-administration have typically been inverted U-shaped,
reflecting lower dose positive effects through higher dose aversive
properties. Nicotine self-administration has been demonstrated in
several species (e.g., mice—Stolerman et al., 1999; rat—Corrigall
and Coen, 1989; Brower et al., 2002; dog—Risner and Goldberg,
1983; nonhuman primate—Sannerud et al., 1994). However, few
studies have examined the relationship between initial sensitiv-
ity to nicotine and nicotine intake. Recent reviews (Changeux,
2010; Tuesta et al., 2011) nicely detail current knowledge about
the involvement of specific nicotinic receptor subtypes, signaling
mechanisms and brain locations in nicotine, as well as other drug,
self-administration behavior, but does not touch on the topic of
initial sensitivity. However, there are genetic differences in sen-
sitivity to behavioral effects of nicotine (Bergstrom et al., 2003;
Boyle and Gill, 2009; Gill and Boyle, 2005; Marks et al., 1989;
Overstreet, 1995; Tritto et al., 2004, 2002), which may  affect self-
administration. Using inbred mouse strains varying in sensitivity to
the first dose of nicotine, Robinson et al. (1996) examined whether
initial sensitivity corresponded with oral self-selection of nicotine,
when the animals were offered the choice of a nicotine-containing
solution vs. water or saccharin water. They found a strong nega-
tive genetic correlation between nicotine intake and sensitivity to
nicotine-induced seizures, suggesting that sensitivity to an appar-
ently aversive effect of nicotine may  limit intake. This relationship
deserves further more careful study in animal models.
As in the studies with humans, pharmacokinetic factors may
also affect nicotine self-administration in mice. Mice with greater
CYP2A5 protein levels (homologous with human CYP2A6 protein),
suggestive of an increased rate of nicotine metabolism, showed
increased nicotine self-administration (Siu et al., 2006). In addition,
rats of the Lewis strain have been found to self-administer more
nicotine than rats of the Fischer 344 strain, and they also appear
to have a more rapid nicotine clearance curve, and perhaps higher
initial peak levels of nicotine (Sziraki et al., 2001).
3.3. Cannabis
3.3.1. Evidence from humans
Both retrospective and prospective studies have examined the
relationship between initial responses to cannabis and subsequent
use of marijuana. Davidson and Schenk (1994) queried 197 college
students about memories of their initial experiences with mari-
juana, using a questionnaire describing both positive and negative
effects. Respondents who experienced more positive effects from
the drug the first time had a shorter latency to their second use
as well as higher lifetime use. Although only a few respondents
reported negative effects from the drug, these negative ratings
did not predict use. Le Strat et al. (2009) conducted a retrospec-
tive analysis of 1472 young cannabis users in New Zealand and
France to investigate the positive and negative effects of cannabis
at first use in relation to cannabis dependence at age 18–21. Partic-
ipants rated the number of positive experiences from the cannabis
at initial use, from 1 to 5 positive responses (e.g., feeling high or
happy). The study found that the odds ratio of developing cannabis
dependence among respondents who  reported 5 positive effects
was 28 times that of becoming dependent with no initial positive
effects, although the categorical classification of ratings limits the
conclusions that can be drawn. Fergusson et al. (2003) conducted
a longitudinal study of 198 respondents who had used cannabis
before age 16, again using the ratings of 1–5 positive experiences.
Participants who  reported 5 positive responses to cannabis at initial
use had an odds ratio of 28.5 for becoming dependent 4 years later,
compared to respondents who  reported no positive effects. As in
the Davidson and Schenk (1994) study, negative experiences were
unrelated to future use. Taken together, these studies suggest that
positive subjective responses to initial marijuana experiences are
predictive of future use. It should be noted, however, that many
factors influence subjective responses to drugs, especially mari-
juana, including expectancies (Kirk et al., 1998), prior drug use and
personality (Chait and Perry, 1992). Thus, although early ratings of
liking marijuana appear to predict future use, the extent to which
this is based on the pharmacological response is not known. This
would only be answerable with controlled studies in which the drug
could be administered for the first time under double blind condi-
tions, which is unlikely to occur. This problem with expectances
also applies to the first use of other classes of drugs in a naturalistic
situation, where users almost always have expectancies regarding
the drug’s identity and its effects.
3.3.2. Evidence from nonhumans
The natural cannabinoid, delta(9)-tetrahydrocannabinol (THC),
and synthetic and endogenous cannabinoid receptor agonists such
as, WIN  55212-2 and anandamide, are self-administered by ani-
mals (monkeys—Justinova et al., 2008; Tanda and Goldberg, 2003;
Tanda et al., 2000; rats—Fattore et al., 2001; Lecca et al., 2006;
mice—Mendizabal et al., 2006). However, some have argued that
cannabinoids are atypical in preclinical animal models with regard
to their profiles as drugs of abuse, because the experimental
conditions under which motivational and reinforcing effects are
displayed are more restricted than for other drugs of abuse (Panagis
et al., 2008). Stimulant and depressant responses to acute cannabi-
noids have been recorded (Bass et al., 2002; Darmani, 2001;
Meschler et al., 2000; Varvel et al., 2007; Wiley et al., 2008), as
have aversive effects (McGregor et al., 1996; Murray and Bevins,
2010). Further, the role of endogenous endocannabinoids and
their receptors more generally in drug reinforcement and other
H. de Wit, T.J. Phillips / Neuroscience and Biobehavioral Reviews 36 (2012) 1565–1576 1571
addiction-related behaviors (Serrano and Parsons, 2011), and in
stress associated responses (Dubreucq et al., 2012; Riebe and
Wotjak, 2011), has more recently received considerable attention.
However, the question of whether initial sensitivity to cannabi-
noids predicts level of cannabinoid intake does not appear to have
been addressed in animal models of cannabinoid use. This is per-
haps partly because self-administration of cannabinoids has been
more difficult to reliably establish in animal models compared to
self-administration of most other addictive drugs.
3.4. Cocaine and other stimulants
3.4.1. Evidence from humans
A few retrospective studies have examined initial response to
cocaine or other stimulants as a predictor of future use. In one
early study (Haertzen et al., 1983) opiate abusers claimed that ini-
tially positive responses to cocaine predicted their later use of the
drug. Davidson et al. (1993) interviewed 44 college students who
reported having used cocaine and found that positive responses
to the drug on initial use predicted a shorter latency to the sec-
ond use. Negative effects did not predict future use. More recently,
Lambert et al. (2006) conducted a study with 202 adults who  had
tried cocaine at least once between ages 16 and 40. Participants
who reported ‘liking’ and ‘wanting’ the drug upon initial exposure
to cocaine were more likely to develop cocaine dependence and
life-time cocaine abuse.
Many laboratory-based studies have examined subjec-
tive responses to stimulant drugs such as amphetamine and
methylphenidate in healthy volunteers, in relation to consumption
or choice (Chait, 1993; de Wit  et al., 1986; Holdstock and de Wit,
2001; Johanson and Uhlenhuth, 1980; Kollins et al., 2001; Lott
et al., 2005; Rush et al., 2001; Volkow et al., 1999). Healthy young
adults vary in their ratings of arousal, liking and anxiety after
low doses of amphetamine. These studies consistently show that
pleasurable, stimulant-like subjective effects are directly related to
consumption of the drug, within the experimental context. In the
studies with amphetamine, most participants experience positive
mood effects from amphetamine during their first experiences
with them, but a small minority experience unpleasant effects such
as anxiety. The mood effects of the drug clearly predict whether
subjects will choose to take the drug again when they are given the
opportunity, on subsequent study sessions. These studies provide
strong support for the idea that pleasurable initial responses are
related to subsequent drug-taking, albeit in the limited context and
abbreviated time frame of a laboratory research study. These acute
drug challenge studies may  help to identify risk factors predicting
future use, including genetic factors (Hart et al., 2012; Lott et al.,
2005), personality and psychiatric symptoms (de Wit  and Bodker,
1994; de Wit  et al., 1987), expectancies (Mitchell et al., 1996) and
brain dopamine receptor density (Volkow et al., 1999). The studies
show systematic relations between acute drug responses and drug
choice in the laboratory.
3.4.2. Evidence from nonhumans
In rats, using genetically heterogeneous groups of animals, loco-
motor response to an acute dose of a psychostimulant may  predict
consumption of the drug. For amphetamine, greater acute sensi-
tivity to locomotor effects of the drug was associated with higher
levels of self-administration (Deminiere et al., 1989; Piazza et al.,
1989). This relationship has also been found for cocaine in some,
but not all, studies (Mandt et al., 2012, 2008; Mantsch et al., 2001).
When approaches have been used that directly investigate poten-
tial genetic relationships between sensitivity and intake, evidence
has also been mixed. In a panel of inbred mouse strains, postpran-
dial drinking of cocaine and sensitivity to the stimulant effects
of cocaine were not strongly related (Seale and Carney, 1991).
However, in rat lines selectively bred for high vs. low locomotor
activity in a novel environment, the high activity line rats exhib-
ited a higher propensity to self-administer cocaine (Cummings
et al., 2011; Davis et al., 2008) and greater sensitivity to quinpi-
role (Flagel et al., 2010), a dopamine D2/D3 receptor agonist, which
would be thought to partly mimic  the effects of cocaine. Unfor-
tunately, to the best of our knowledge, drug sensitivity has not
been fully characterized in these lines, although one study showed
no difference between the lines in activation to an initial treat-
ment with a 15 mg/kg dose of cocaine (Garcia-Fuster et al., 2010).
A mouse line selectively bred for higher oral intake of metham-
phetamine (Shabani et al., 2011; Wheeler et al., 2009) that also
exhibits greater operant methamphetamine self-administration
(Shabani et al., 2012a)  exhibits greater acute locomotor activa-
tion to methamphetamine (Shabani et al., 2011). However, mice
bred for extreme sensitivity to the stimulant effects of metham-
phetamine voluntarily consume less methamphetamine compared
to the oppositely selected low stimulation line (Kamens et al.,
2005). The authors suggest two  interpretations. First, the mice bred
for high stimulation may  require less MA to experience reward-
ing effects and thus, may  choose to consume less MA  compared to
the mice bred for low stimulation. Alternatively, extreme sensitiv-
ity to the stimulant effect could be aversive, and thus, avidity for
methamphetamine is reduced. The positive association of metham-
phetamine intake and stimulation in the lines bred for high and low
MA drinking was seen only at a higher 4 mg/kg dose, whereas the
stimulation selected lines were bred based on their response to
2 mg/kg methamphetamine. It is possible that the use of the lower
dose resulted in a more profound sensitivity, as one would expect
to identify more sensitive animals with this low dose, than with a
higher dose.
In addition to the association of sensitivity to stimulant effects
with intake, aversive effects of methamphetamine have been stud-
ied. Mice bred for low drinking of methamphetamine solutions
showed profound conditioned aversion induced by a single treat-
ment with methamphetamine that was not seen in the high
drinking line mice, even after multiple treatments (Shabani et al.,
2012b; Wheeler et al., 2009). These results are similar to those for
alcohol, and suggest that high sensitivity to the aversive effects of
methamphetamine protects against high levels of intake.
Another source of information about initial responses to drugs
and drug-taking in animal models comes from studies of dis-
criminative stimulus effects. For example, rats that were more
sensitive to the activating effects of amphetamine were also
more sensitive to its discriminative stimulus effects (Bevins et al.,
1997). In a study in non-human primates investigating cocaine
self-administration and drug discrimination, at least one dose sup-
ported only self-administration without serving as a discriminative
stimulus. This suggests that cocaine reinforcement can occur in the
absence of a cocaine-like discriminative stimulus effect (Martelle
and Nader, 2009). However, once a drug has been established as
a discriminative stimulus, it can substantially increase subsequent
self-administration (Panlilio et al., 1996). Thus, sensitivity to drug
discriminative stimulus effects has the potential to influence drug
intake.
3.5. Caffeine
3.5.1. Evidence from humans
In an early retrospective study, Haertzen et al. (1983) queried
opiate abusers about their initial responses to caffeine. Although
these participants claimed that their initial responses to heroin and
cocaine predicted subsequent use of these drugs, they reported that
their initial responses to caffeine were unpleasant and not related
to future use. To our knowledge, no longitudinal studies have exam-
ined the initial responses to caffeine in relation to future use. One
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challenge to conducting longitudinal studies on early responses
to caffeine is that caffeine use begins early (Frary et al., 2005),
usually in the form of caffeinated sodas. Because of the widespread
use of these drinks and the relatively subtle acute effects of low
doses of caffeine, it is difficult to assess early responses under non-
controlled conditions.
Several laboratory-based studies have examined acute sub-
jective responses to caffeine in adults as predictors of choice or
consumption of the drug in the laboratory (Griffiths and Woodson,
1988; Stern et al., 1989). These studies support the idea that pleas-
ant caffeine-induced effects such as mental arousal and decreased
fatigue predict drug choice, whereas unpleasant effects such as
jitteriness or anxiety predict non-choice of caffeine. There is also
indirect evidence that negative subjective responses predict low
caffeine use. Patients with panic disorder experience anxiety from
caffeine, and consume less of it than healthy controls (Boulenger
et al., 1984; Charney et al., 1985; Lee et al., 1988; Uhde et al., 1984).
Moreover, in both panic disorder patients and healthy controls,
individuals with a certain polymorphism of the adenosine receptor
gene are more likely to experience anxiety from an acute dose of the
drug (Alsene et al., 2003; Charney et al., 1985; Childs et al., 2008; Lee
et al., 1988; Uhde et al., 1984). Yang et al. (2010) recently reviewed
evidence for the contribution of genetic factors in responses to
caffeine in humans and found evidence for genetic contributions
to the positive vs. negative subjective or physiological effects of
caffeine (e.g., feelings of arousal, anxiety or insomnia), level of
habitual caffeine consumption and caffeine metabolism. Indeed,
recent genome-wide association analyses involving thousands of
people have identified significant associations with caffeine intake
for single nucleotide polymorphisms that suggest a role for genes
involved in the metabolism of caffeine or the constituents of coffee
(Amin et al., 2011; Cornelis et al., 2011; Sulem et al., 2001). Whether
there is a role for these genes in caffeine sensitivity has not been
explored.
3.5.2. Evidence from nonhumans
Relatively few studies have examined initial acute responses to
caffeine in relation to self-administration in nonhumans. However,
mechanistic studies point to a role for the A2A receptor subtype in
both caffeine consumption and locomotor activation (El Yacoubi
et al., 2000, 2005; Yang et al., 2009), using A2A knockout mice.
In another study using A1 knockout mice, no evidence for a role
of the A1 receptor subtype in caffeine consumption was found
(Rieg et al., 2007) and a lesser role than that of the A2A recep-
tor was found for caffeine-induced locomotor stimulation (Yang
et al., 2009). Though these are interesting results that suggest some
common mechanisms underlying sensitivity and intake, they do
not directly address the question of whether initial sensitivity to
caffeine predicts future intake.
3.6. Opiates
3.6.1. Evidence from humans
In an early retrospective study, Haertzen et al. (1983) reported
that opiate abusers liked their first experiences with heroin and
other opiates more than they liked 11 other types of drugs that
they had used, and that opiates were their preferred and primary
drug of choice from the beginning. Conducting a retrospective study
that included non-drug-abusing volunteers, Bieber et al. (2008)
recruited 20 opioid abusers in a treatment center and 20 controls,
all of whom had first received opiates for pain control. Participants
completed a retrospective questionnaire reporting the feelings of
euphoria and well-being they experienced upon their first use of an
opiate drug. The drug-abusing participants reported having experi-
enced greater euphoria upon their first use than the control group.
There are no longitudinal studies on initial responses to opiates
in relation to subsequent abuse, although such information would
be valuable because of the widespread medical use of opiates as
well as the recently increasing prevalence of abuse (Manubay et al.,
2011; Maxwell, 2011). Fortunately, only a very small proportion of
patients who  receive opiates for pain control progress to develop
problems with abuse (Hojsted and Sjogren, 2007).
Controlled studies with healthy volunteers do indicate that
acute responses to opiates vary markedly across individuals (Comer
et al., 2010; Lasagna et al., 1955; McAuliffe, 1975; Zacny and
Gutierrez, 2003; Zacny et al., 1994, 1992), from pleasant to unpleas-
ant. Whether these initial subjective effects of opiates predict
repeated use or choice over a placebo has not yet been studied.
3.6.2. Evidence from nonhumans
The question of the relationship between initial sensitivity and
self-administration of opiates has received relatively little atten-
tion in nonhuman studies. C57BL/6J inbred strain mice exhibit a
larger initial stimulant response to morphine than do DBA/2J mice
(Belknap et al., 1989), and DBA/2J mice exhibit a locomotor depres-
sant response to morphine early after administration (Phillips
et al., 1994). Consistent with the idea that stimulation is related
to reward, morphine supports intravenous self-administration in
C57BL/6J, but not DBA/2J mice (Elmer et al., 2010). These data
are in agreement with two-bottle choice drinking studies show-
ing greater morphine consumption in the C57BL/6J than DBA/2J
strain (Belknap et al., 1993; Horowitz et al., 1977). Thus, for these
two strains, the data suggest that greater initial sensitivity to stim-
ulant effects of an opioid is associated with greater reinforcement,
and greater sensitivity to depressant effects reduces consump-
tion. However, in another set of 4 strains, oral self-administration
of the opioid, etonitazene, was  not associated with sensitivity
to etonitazene-induced locomotor stimulation or other effects
(Elmer et al., 1995). A few studies in single gene mutant mice
are also relevant. Not surprisingly, mu-opioid receptor knockout
mice do not self-administer morphine and show reduced sen-
sitivity to morphine-induced locomotor stimulation (Sora et al.,
2001). In mice lacking protein kinase C epsilon, increased sus-
ceptibility to morphine self-administration was  associated with
enhanced sensitivity to morphine’s analgesic effects, compared to
their non-mutant counterparts (Newton et al., 2007). Mice lacking
the NK1 receptor, the preferred receptor for substance P, exhibited
heightened sensitivity to locomotor depressant effects of mor-
phine, as well as reduced self-administration of morphine (Ripley
et al., 2002). These results mirror those for DBA/2J, compared to
C57BL/6J, mice. Overall, the data support a positive relationship
between sensitivity to stimulant effects of opioids and opioid self-
administration and a negative relationship between sensitivity to
depressant effects of opioids and opioid self-administration.
4. Conclusions
So, do initial responses to drugs predict future use or abuse? We
have reviewed the limited evidence that early responses to drugs
predict use or abuse in humans and nonhumans. First, we con-
firm that there are marked individual differences in initial acute
responses to drugs, and some of these differences are genetic.
Second, we confirm that certain direct effects of drugs appear to
be protective against future use, such as, in humans, the flushing
response to alcohol and perhaps the anxiety response to caffeine.
Third, we  find some evidence that euphoria and stimulation facili-
tate repeated use across several classes of drugs, including opiates
and stimulants in humans, although the evidence for stimulants in
animals is more mixed. From this review, we conclude that initial
positive or negative effects of drugs probably influence the likeli-
hood of continuing use in the short term, but their relationship with
H. de Wit, T.J. Phillips / Neuroscience and Biobehavioral Reviews 36 (2012) 1565–1576 1573
full dependence is less clear. By definition, early use must precede
escalation of use, which precedes dependence. Therefore, there is
likely to be some relation between initial responses and depen-
dence. However, the contribution of the initial acute effect of the
drug is probably minor, compared to the multitude of other vari-
ables that contribute to excessive drug use. These include cognitive
factors related to decision-making, physiological factors related to
stress, as well as processes of neural adaptation, learning, tolerance,
sensitization, and physical dependence that only develop with con-
tinued ingestion of the drugs.
We have identified gaps in the literature, methodological chal-
lenges and directions for future research. Longitudinal research
documenting initial drug effects, and following probands across
their drug-taking trajectories, is the gold standard. Longitudinal
studies would be of particular interest with opiates, for example,
and with cigarette smokers. Animal models also offer a valuable tool
for studying this relationship, and for particular studying genetic
factors. Initial drug responses can easily be obtained in naïve ani-
mals, genetic characteristics and context can be controlled and drug
dose and purity are not an issue. Relatively few nonhuman studies
have followed the complete time progression of the dependence
process, beyond the initial self-administration period. To coordi-
nate the human and nonhuman studies, there is a need to develop
and refine drug-abuse related measures that are directly compara-
ble in humans and animals (Crabbe et al., 2010; O’Dell and Khroyan,
2009; Stephens et al., 2011). Although the relationship between ini-
tial drug sensitivity and risk for abuse or dependence is not likely
to be simple, further exploration is likely to solidify which traits are
of greatest relevance and thus, of greatest predictive value.
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